172 related articles for article (PubMed ID: 34435915)
1. MSX2 represses tumor stem cell phenotypes within oral squamous cell carcinomas via SOX2 degradation.
Keyimu R; Tuerdi M; Zhao Z
Exp Biol Med (Maywood); 2021 Dec; 246(24):2660-2670. PubMed ID: 34435915
[TBL] [Abstract][Full Text] [Related]
2. The FBXW2-MSX2-SOX2 axis regulates stem cell property and drug resistance of cancer cells.
Yin Y; Xie CM; Li H; Tan M; Chen G; Schiff R; Xiong X; Sun Y
Proc Natl Acad Sci U S A; 2019 Oct; 116(41):20528-20538. PubMed ID: 31548378
[TBL] [Abstract][Full Text] [Related]
3. Lin28B/Let-7 Regulates Expression of Oct4 and Sox2 and Reprograms Oral Squamous Cell Carcinoma Cells to a Stem-like State.
Chien CS; Wang ML; Chu PY; Chang YL; Liu WH; Yu CC; Lan YT; Huang PI; Lee YY; Chen YW; Lo WL; Chiou SH
Cancer Res; 2015 Jun; 75(12):2553-65. PubMed ID: 25858147
[TBL] [Abstract][Full Text] [Related]
4. Hyaluronan-CD44v3 interaction with Oct4-Sox2-Nanog promotes miR-302 expression leading to self-renewal, clonal formation, and cisplatin resistance in cancer stem cells from head and neck squamous cell carcinoma.
Bourguignon LY; Wong G; Earle C; Chen L
J Biol Chem; 2012 Sep; 287(39):32800-24. PubMed ID: 22847005
[TBL] [Abstract][Full Text] [Related]
5. SOX2 promotes a cancer stem cell-like phenotype and local spreading in oral squamous cell carcinoma.
Sacco A; Battaglia AM; Santamaria G; Buffone C; Barone S; Procopio A; Lavecchia AM; Aversa I; Giorgio E; Petriaggi L; Cristofaro MG; Biamonte F; Giudice A
PLoS One; 2023; 18(12):e0293475. PubMed ID: 38096163
[TBL] [Abstract][Full Text] [Related]
6. SHH Expression Is Significantly Associated With Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma.
Cierpikowski P; Lis-Nawara A; Bar J
Anticancer Res; 2021 Nov; 41(11):5405-5413. PubMed ID: 34732409
[TBL] [Abstract][Full Text] [Related]
7. Sox2 expression involvement in the oncogenicity and radiochemoresistance of oral cancer stem cells.
Chou MY; Hu FW; Yu CH; Yu CC
Oral Oncol; 2015 Jan; 51(1):31-9. PubMed ID: 25456004
[TBL] [Abstract][Full Text] [Related]
8. Acquisition cancer stemness, mesenchymal transdifferentiation, and chemoresistance properties by chronic exposure of oral epithelial cells to arecoline.
Wang TY; Peng CY; Lee SS; Chou MY; Yu CC; Chang YC
Oncotarget; 2016 Dec; 7(51):84072-84081. PubMed ID: 27557511
[TBL] [Abstract][Full Text] [Related]
9. CD47-SIRPĪ± Signaling Induces Epithelial-Mesenchymal Transition and Cancer Stemness and Links to a Poor Prognosis in Patients with Oral Squamous Cell Carcinoma.
Pai S; Bamodu OA; Lin YK; Lin CS; Chu PY; Chien MH; Wang LS; Hsiao M; Yeh CT; Tsai JT
Cells; 2019 Dec; 8(12):. PubMed ID: 31861233
[TBL] [Abstract][Full Text] [Related]
10. High expression of ALDH1 and SOX2 diffuse staining pattern of oral squamous cell carcinomas correlates to lymph node metastasis.
Michifuri Y; Hirohashi Y; Torigoe T; Miyazaki A; Kobayashi J; Sasaki T; Fujino J; Asanuma H; Tamura Y; Nakamori K; Hasegawa T; Hiratsuka H; Sato N
Pathol Int; 2012 Oct; 62(10):684-9. PubMed ID: 23005595
[TBL] [Abstract][Full Text] [Related]
11. Cancer Cell CD44 Mediates Macrophage/Monocyte-Driven Regulation of Head and Neck Cancer Stem Cells.
Gomez KE; Wu F; Keysar SB; Morton JJ; Miller B; Chimed TS; Le PN; Nieto C; Chowdhury FN; Tyagi A; Lyons TR; Young CD; Zhou H; Somerset HL; Wang XJ; Jimeno A
Cancer Res; 2020 Oct; 80(19):4185-4198. PubMed ID: 32816856
[TBL] [Abstract][Full Text] [Related]
12. IL-1RA promotes oral squamous cell carcinoma malignancy through mitochondrial metabolism-mediated EGFR/JNK/SOX2 pathway.
Yuan SF; Wang YM; Chan LP; Hung AC; Nguyen HDH; Chen YK; Hu SC; Lo S; Wang YY
J Transl Med; 2023 Jul; 21(1):473. PubMed ID: 37461111
[TBL] [Abstract][Full Text] [Related]
13. CD44(high)CD24(low) molecular signature determines the Cancer Stem Cell and EMT phenotype in Oral Squamous Cell Carcinoma.
Ghuwalewala S; Ghatak D; Das P; Dey S; Sarkar S; Alam N; Panda CK; Roychoudhury S
Stem Cell Res; 2016 Mar; 16(2):405-17. PubMed ID: 26926234
[TBL] [Abstract][Full Text] [Related]
14. Cancer Stem Cell Markers, CD44 and ALDH1, for Assessment of Cancer Risk in OPMDs and Lymph Node Metastasis in Oral Squamous Cell Carcinoma.
Dhumal SN; Choudhari SK; Patankar S; Ghule SS; Jadhav YB; Masne S
Head Neck Pathol; 2022 Jun; 16(2):453-465. PubMed ID: 34655409
[TBL] [Abstract][Full Text] [Related]
15. Organotypic culture of normal, dysplastic and squamous cell carcinoma-derived oral cell lines reveals loss of spatial regulation of CD44 and p75 NTR in malignancy.
Dalley AJ; AbdulMajeed AA; Upton Z; Farah CS
J Oral Pathol Med; 2013 Jan; 42(1):37-46. PubMed ID: 22643025
[TBL] [Abstract][Full Text] [Related]
16. Association of OCT4, SOX2, and NANOG expression with oral squamous cell carcinoma progression.
Fu TY; Hsieh IC; Cheng JT; Tsai MH; Hou YY; Lee JH; Liou HH; Huang SF; Chen HC; Yen LM; Tseng HH; Ger LP
J Oral Pathol Med; 2016 Feb; 45(2):89-95. PubMed ID: 26211876
[TBL] [Abstract][Full Text] [Related]
17. SALL4 promotes cancer stem-like cell phenotype and radioresistance in oral squamous cell carcinomas via methyltransferase-like 3-mediated m6A modification.
Huang J; Li H; Yang Z; Liu R; Li Y; Hu Y; Zhao S; Gao X; Yang X; Wei J
Cell Death Dis; 2024 Feb; 15(2):139. PubMed ID: 38355684
[TBL] [Abstract][Full Text] [Related]
18. Stress-triggered YAP1/SOX2 activation transcriptionally reprograms head and neck squamous cell carcinoma for the acquisition of stemness.
Omori H; Sato K; Nakano T; Wakasaki T; Toh S; Taguchi K; Nakagawa T; Masuda M
J Cancer Res Clin Oncol; 2019 Oct; 145(10):2433-2444. PubMed ID: 31485767
[TBL] [Abstract][Full Text] [Related]
19. High CD44 Immunoexpression Correlates with Poor Overall Survival: Assessing the Role of Cancer Stem Cell Markers in Oral Squamous Cell Carcinoma Patients from the High-Risk Population of Pakistan.
Adnan Y; Ali SMA; Farooqui HA; Kayani HA; Idrees R; Awan MS
Int J Surg Oncol; 2022; 2022():9990489. PubMed ID: 35296132
[TBL] [Abstract][Full Text] [Related]
20. Effects of Maackia amurensis seed lectin (MASL) on oral squamous cell carcinoma (OSCC) gene expression and transcriptional signaling pathways.
Hamilton KL; Sheehan SA; Retzbach EP; Timmerman CA; Gianneschi GB; Tempera PJ; Balachandran P; Goldberg GS
J Cancer Res Clin Oncol; 2021 Feb; 147(2):445-457. PubMed ID: 33205348
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
